(Q33333673)

25 July 2017

Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma (English)

1 reference

25 July 2017

0 references

hepatocellular carcinoma

1 reference

T S Yang

1

1 reference

25 July 2017

Y C Lin

2

1 reference

25 July 2017

J S Chen

3

1 reference

25 July 2017

H M Wang

4

1 reference

25 July 2017

C H Wang

5

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 August 2000

1 reference

25 July 2017

1 reference

25 July 2017

89

1 reference

25 July 2017

4

1 reference

25 July 2017

750-756

1 reference

Treatment of hepatocellular carcinoma: too many options?

25 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Clinical trials in primary hepatocellular carcinoma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820000815%2989%3A4%3C750%3A%3AAID-CNCR5%3E3.0.CO%3B2-R

10.1002/1097-0142(20000815)89:4<750::AID-CNCR5>3.0.CO;2-R

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference